https://scholars.lib.ntu.edu.tw/handle/123456789/535568
標題: | A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza | 作者: | HSIANG-CHI KUNG KUO-CHIN HUANG Kao T.-M. Lee Y.-C. Chang F.-Y. Wang N.-C. Liu Y.-C. Lee W.-S. Liu H.-J. Chen C.-I. Chen C.-H. LI-MIN HUANG SZU-MIN HSIEH |
公開日期: | 2010 | 卷: | 28 | 期: | 45 | 起(迄)頁: | 7337-7343 | 來源出版物: | Vaccine | 摘要: | We conducted a multi-center, randomized, laboratory-blinded clinical trial in 185 healthy adults (<60 years) and 107 elders (>60 years) to examine the immunogenicity and safety of different doses of an inactivated, monovalent, non-adjuvanted, split vaccine against the 2009 pandemic influenza A (H1N1) virus. The 186 adults were assigned to three treatment groups, i.e., one 15μg hemagglutination (HA) antigen dose, two 15μg or 30μg HA doses in 3 weeks apart, and the 107 elders were treated with two 15μg or 30μg doses in 3 weeks apart. Prior to the vaccination, 4.8% subjects had hemagglutination-inhibition (HAI) antibody titers of 1:40 or more. By day 21 post-vaccination of one dose of 15μg HA, the seroprotective rate was 95.1% and 75.5% in subjects <60 and >65 years of age, respectively; by day 21 post the second 15μg HA dose, the seroprotective rates were 93.2% and 73.1%, respectively. The seroprotective rates for recipients of 30μg HA antigen by day 21 were 95.2% for subjects <60 years and 81.1% for subjects >65 years of age, that was boosted to 98.3% and 80.4%, respectively with a second dose of 30μg HA antigen. No vaccine-related serious adverse events occurred. The data indicated a single 15μg HA dose of the vaccine induced a protective immune response in most adults, including the elders >60 years of age, and a booster dose at the third week did not render a higher level of antibody response. ? 2010 Elsevier Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-77957753780&doi=10.1016%2fj.vaccine.2010.08.073&partnerID=40&md5=d9d354cf82e0349ef15bfd0b96fc515f https://scholars.lib.ntu.edu.tw/handle/123456789/535568 |
ISSN: | 0264-410X | DOI: | 10.1016/j.vaccine.2010.08.073 | SDG/關鍵字: | influenza vaccine; adult; aged; antibody response; antibody titer; article; chemotherapy induced emesis; chest tightness; clinical trial; controlled clinical trial; controlled study; coughing; dizziness; drug fever; drug safety; ecchymosis; eye disease; face edema; female; headache; hemagglutination; hemagglutination inhibition; human; immune response; immunogenicity; influenza A (H1N1); influenza vaccination; Influenza virus A H1N1; limb movement; major clinical study; malaise; male; multicenter study; myalgia; nausea; nose congestion; pain; pandemic influenza; phase 2 clinical trial; priority journal; respiratory distress; respiratory tract infection; side effect; single blind procedure; sore throat; swelling; Adult; Aged; Aged, 80 and over; Antibodies, Viral; Antibody Formation; Epidemics; Female; Hemagglutination Inhibition Tests; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Taiwan; Vaccination; Young Adult |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。